Harold L Atkins

List of Publications by Year
in descending order

70 papers	2,250 citations	257357 24 h-index	223716 46 g-index
82 all docs	82 docs citations	82 times ranked	3336 citing authors

#	Article	IF	Citations
1	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585.	6.3	296
2	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	4.5	199
3	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
4	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Annals of Neurology, 2013, 73, 341-354.	2.8	130
5	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfusion Medicine Reviews, 2019, 33, 98-110.	0.9	124
6	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine, 2015, 21, 530-536.	15.2	118
7	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	7.7	77
8	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurology, 2016, 73, 652.	4.5	71
9	Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned. Neurotherapeutics, 2013, 10, 68-76.	2.1	70
10	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
11	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	3.7	65
12	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
13	Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. Stem Cell Reports, 2017, 8, 1190-1201.	2.3	55
14	Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 1039-1044.	2.0	53
15	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 834.	2.2	51
16	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e598.	3.1	50
17	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation, 2010, 16, 1076-1083.	2.0	46
18	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nature Communications, 2015, 6, 6410.	5.8	42

#	Article	IF	Citations
19	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative Medicine, 2015, 10, 897-911.	0.8	41
20	Immune Ablation Followed by Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Poor Prognosis Multiple Sclerosis. Methods in Molecular Biology, 2009, 549, 231-246.	0.4	39
21	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 420-431.	1.4	33
22	Autologous Stem Cell Transplantation for Stiff Person Syndrome. JAMA Neurology, 2014, 71, 1296.	4.5	29
23	Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseaseâ€"Is It Now Ready for PrimeÂTime?. Biology of Blood and Marrow Transplantation, 2012, 18, S177-S183.	2.0	28
24	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2096-2101.	2.0	27
25	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 767-775.	1.7	20
26	A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102945.	0.9	19
27	Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1764-1772.	1.4	18
28	Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029082.	2.9	18
29	Immunoablative therapy as a treatment aggressive multiple sclerosis. Neurologic Clinics, 2005, 23, 273-300.	0.8	17
30	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, e019321.	0.8	16
31	Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. Blood, 2014, 124, 3996-3996.	0.6	16
32	Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. Neurotherapeutics, 2017, 14, 888-893.	2.1	14
33	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1055-1066.	1.4	14
34	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1298-1302.	2.0	14
35	The stem cell market and policy options: a call for clarity. Journal of Law and the Biosciences, 2018, 5, 743-758.	0.8	13
36	Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials. Research Involvement and Engagement, 2020, 6, 61.	1.1	12

#	Article	IF	Citations
37	Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial. Cmaj, 2014, 186, E427-E434.	0.9	11
38	Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. Journal of the Neurological Sciences, 2014, 336, 132-137.	0.3	11
39	Stem Cell Transplantation to Treat Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 153.	3.8	11
40	Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. Systematic Reviews, 2021, 10, 35.	2.5	11
41	Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial. BMJ Open, 2021, 11, e043929.	0.8	10
42	Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2014, 3, 129-135.	0.9	8
43	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2466-2470.	2.0	7
44	Does Resetting the Immune System Fix Multiple Sclerosis?. Canadian Journal of Neurological Sciences, 2020, 47, 1-10.	0.3	7
45	Hematologistsâ€™ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. Trials, 2021, 22, 230.	0.7	7
46	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. Transplantation, 2022, 106, 562-574.	0.5	7
47	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS â€“ YES. Multiple Sclerosis Journal, 2016, 22, 1258-1259.	1.4	5
48	Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. Multiple Sclerosis Journal, 2020, 27, 135245852091793.	1.4	5
49	One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies. Molecular Therapy, 2016, 24, 2039-2042.	3.7	3
50	The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. Hematology, Transfusion and Cell Therapy, 2019, 41, 285-291.	0.1	3
51	Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Canadian Journal of Neurological Sciences, 2021, , 1-7.	0.3	3
52	Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	2
53	Immunoablation and aHSCT for aggressive multiple sclerosis â€“ Authors' reply. Lancet, The, 2017, 389, 908.	6.3	2
54	Total body irradiation (18â€‰Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. Bone Marrow Transplantation, 2020, 55, 1454-1456.	1.3	2

#	Article	IF	Citations
55	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	1.2	2
56	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. BMJ Open, 2021, 11, e046707.	0.8	2
57	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. Multiple Sclerosis and Related Disorders, 2022, 61, 103779.	0.9	2
58	The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virotherapy, 2015, 4, 13.	6.0	1
59	Building Canadian capacity for CARâ€T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. British Journal of Haematology, 2020, 191, e14-e19.	1.2	1
60	A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 4519-4519.	0.6	1
61	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 5782-5782.	0.6	1
62	Another brick in the wall: further evidence supporting the role of haematopoietic stem cell transplantation in treating multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 496-496.	0.9	0
63	Importance of the hematology laboratory in infectious disease diagnosis by morphology: Four educational case studies. International Journal of Laboratory Hematology, 2020, 42, 133-137.	0.7	0
64	Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation â€“ A Retrospective Analysis. Hematology, Transfusion and Cell Therapy, 2020, 43, 437-442.	0.1	0
65	A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma.. Blood, 2005, 106, 2929-2929.	0.6	0
66	Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation. Blood, 2016, 128, 2186-2186.	0.6	0
67	Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience. Blood, 2018, 132, 4624-4624.	0.6	0
68	Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?. Blood, 2018, 132, 5159-5159.	0.6	0
69	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. Blood, 2019, 134, 3263-3263.	0.6	0
70	Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol. Current Protocols, 2022, 2, e437.	1.3	0